AHA blog: PhRMA-led coalition seeks to dismantle 340B at patients’ expense
The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug Pricing Program so that they can continue to pad their billion-dollar bottom lines,” writes Bharath Krishnamurthy, director of health analytics and policy for the AHA. “The self-serving policy proposals outlined by this new alliance directly contravene Congress’ oft-demonstrated intent to preserve the 340B program over the last 30 years. Those most impacted by this coalition’s assault on 340B are the millions of patients who will lose access to lifesaving medicines and to other vital health care services supported by the program.” READ MORE
Related News Articles
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…
Perspective
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…